PGBD1 Antibody

What is PGBD1 and why is it important in neurological research?

PGBD1 (PiggyBac Transposable Element Derived 1) belongs to the piggyBac family of proteins found in diverse animals, which are transposases related to the canonical piggyBac transposon from the moth Trichoplusia ni . This gene product is specifically expressed in the brain, with highest expression in the cerebellar hemisphere (median 18.59 TPM, n=215) and cerebellum (median 17.49 TPM, n=241) according to GTEx data .

PGBD1 exhibits distinct expression patterns in neuronal cells, with single-cell analyses showing enrichment in excitatory/inhibitory neurons followed by glial cells (oligodendrocytes, oligodendrocyte precursor cells, and astrocytes) . Importantly, PGBD1 is expressed at higher levels in neuronal progenitor cells (NPCs) compared to differentiated neurons, suggesting developmental regulation .

The protein plays a critical role in regulating neuronal cell differentiation, nervous system development, and neurogenesis . Genome-wide analysis through ChIP-exo has revealed that PGBD1 binds predominantly in or around protein-coding genes (approximately 84%), particularly in upstream regulatory regions and introns .

What applications are recommended for PGBD1 antibodies in neuroscience research?

PGBD1 antibodies have been successfully employed in multiple applications for neuroscientific research, with varying degrees of validation:

For studying PGBD1's role in neuronal differentiation, ChIP-exo and immunofluorescence applications have provided valuable insights into binding patterns and cellular localization . When investigating PGBD1's regulatory effects on neuronal gene expression, combining Western blotting with qPCR validation of differentially expressed genes has proven effective .

How should I validate the specificity of a PGBD1 antibody for neuronal studies?

Validating PGBD1 antibody specificity is crucial for neurological research due to the protein's tissue-specific expression patterns. A comprehensive validation approach should include:

• Positive controls: Use cell lines with known PGBD1 expression (HeLa, Jurkat, 293, K562 cells have all shown detectable PGBD1 expression by Western blot) .

• Knockout/knockdown validation: Compare antibody signal between wildtype cells and PGBD1-depleted cells. For instance, researchers have successfully used miRNA knockdown approaches and CRISPR-KRAB-MeCP2 repressor techniques to deplete PGBD1 in NPCs .

• Band size verification: Confirm detection at the predicted molecular weight of 92.5-93 kDa on Western blots .

• Cross-reactivity testing: If studying non-human samples, evaluate potential cross-reactivity, though most commercial antibodies are currently validated for human samples only .

• Immunogen verification: Consider antibody epitope location - available PGBD1 antibodies target different regions including C-terminal (fusion protein) , internal region (synthesized peptide, residues 347-375) , and N-terminal portions.

For ChIP-exo applications specifically, validation should include electrophoretic mobility shift assay (EMSA) with fluorescently labeled oligonucleotides containing PGBD1 binding motifs, as demonstrated with HA-tagged PGBD1 protein .

What is the optimal storage and handling protocol for PGBD1 antibodies?

Proper storage and handling of PGBD1 antibodies is essential for maintaining reactivity and specificity. Based on manufacturer recommendations:

• Storage temperature: Store at -20°C for most formulations . Some recombinant proteins may require -80°C storage .

• Aliquoting: Divide into single-use aliquots to avoid repeated freeze-thaw cycles, which can degrade antibody performance . Limit to 2-3 freeze-thaw cycles when using recombinant proteins .

• Buffer conditions: Most PGBD1 antibodies are supplied in PBS with additives for stability:

  • PBS with 0.02% sodium azide, 0.5% BSA, and 50% glycerol (pH 7.4)

  • PBS with 0.09% sodium azide

  • Rabbit IgG in pH 7.4 PBS, 0.05% NaN3, 40% glycerol

  • For recombinant proteins: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol

• Working dilution preparation: Dilute antibodies immediately before use in appropriate buffer. For Western blotting, a recommended dilution range of 1:1000-1:10000 has been validated .

• Thawing procedure: For frozen recombinant proteins, thaw on ice before preparing dilutions .

When planning long-term studies, consider antibody stability over time and maintain consistent lots when possible to ensure reproducibility across experiments.

How can I design ChIP-exo experiments to study PGBD1 DNA binding patterns in neural progenitor cells?

ChIP-exo has proven effective for identifying PGBD1 binding motifs and genomic distribution in neural cells. A comprehensive experimental design should include:

• Cell type selection: Based on PGBD1 expression data, neural progenitor cells (NPCs) show higher expression than differentiated neurons, making them optimal for studying PGBD1 binding patterns . Consider using hESC_H1-derived NPCs as successfully employed in published studies .

• Antibody selection and validation: Use ChIP-grade antibodies validated for human PGBD1. Verify antibody specificity in your cell system before proceeding with ChIP-exo.

• Experimental controls:

  • Input controls (non-immunoprecipitated chromatin)

  • IgG controls (non-specific antibody)

  • Consider parallel experiments in both NPCs and neurons to identify cell-type-specific binding patterns

• Motif analysis approach:

  • Two distinct PGBD1 binding motifs (Motif-1 and Motif-2) have been identified

  • Analyze ChIP-exo peaks using motif discovery tools

  • Validate identified motifs using EMSA with fluorescently labeled oligonucleotides and purified HA-tagged PGBD1 protein

• Genomic distribution analysis:

  • Focus on gene regulatory regions, as PGBD1 binding predominates in or around protein-coding genes (84%)

  • Pay particular attention to first and last introns, 5' and 3' UTRs, and regions 1kb upstream of TSS

  • Intersect PGBD1 ChIP-exo peaks with H3K4me1 histone mark signals to identify regulatory regions

For functional validation of binding sites, researchers have successfully coupled PGBD1 knockdown approaches with transcriptome analysis to identify differentially expressed genes with PGBD1 binding sites .

What methodological approaches can be used to study PGBD1's role in paraspeckle formation and NEAT1 regulation?

PGBD1 has been shown to play a key role in repressing NEAT1_2 expression and subsequently regulating paraspeckle formation in neural progenitor cells. To investigate this regulatory pathway:

• PGBD1 depletion strategies:

  • miRNA knockdown approach combining RNAi and Sleeping Beauty mediated transposition (demonstrated to effectively deplete PGBD1 in NPCs)

  • CRISPR-KRAB-MeCP2 repressor approach to specifically inactivate the PGBD1 promoter

  • Note: Complete knockout strategies may interfere with cell renewal, preventing stable maintenance of colonies

• NEAT1 isoform quantification:

  • Use quantitative PCR (qPCR) to measure both NEAT1_1 and NEAT1_2 isoforms

  • PGBD1 depletion primarily affects NEAT1_2 levels, with approximately 17-fold elevation observed in NPCs

• Visualization of paraspeckles:

  • Fluorescence in situ hybridization (FISH) to detect NEAT1_2

  • Immunofluorescence staining for SFPQ (paraspeckle marker)

  • Co-localization analysis to confirm paraspeckle formation

• ChIP analysis of PGBD1 binding to NEAT1 locus:

  • ChIP-exo to identify binding of both Motif-1 and Motif-2 over the NEAT1 locus

  • Focus on promoter and gene body regions of NEAT1

  • Note PGBD1 binding is specific to NPCs, with no significant binding signal detectable in differentiated neurons

• Transcriptional pausing analysis:

  • Genome-wide GRO-seq datasets in NPCs can measure nascent RNA

  • Calculate transcriptional pausing by computing the quotient of binned expression per analyzed feature and the entire gene body

This integrated approach has revealed that PGBD1 plays a key role in suppressing paraspeckle formation in neural progenitor cells by repressing NEAT1_2 transcription .

How can I analyze PGBD1's evolutionary conservation and selection pressure using antibody-based approaches?

Studying PGBD1's evolutionary conservation can provide insights into its functional importance across species. While sequence-based analyses show PGBD1 is largely under purifying selection (Ka/Ks ratio ≤ 0.35), antibody-based approaches can illuminate protein-level conservation:

• Cross-species reactivity testing:

  • Current commercial PGBD1 antibodies are predominantly validated for human samples

  • Test cross-reactivity with PGBD1 orthologs from other species, particularly primates where sequence conservation is highest

  • Western blot analysis across species can reveal conservation of protein size and expression patterns

• Domain-specific antibody application:

  • The KRAB domain shows evidence of adaptive evolution in some lineages

  • Domain-specific antibodies can help identify structural conservation versus adaptation

  • Target antibodies to positions 227V and 252M, which have been identified as positively selected sites

• Protein interaction conservation analysis:

  • Co-immunoprecipitation with PGBD1 antibodies followed by mass spectrometry can identify interacting partners

  • Compare interaction networks across species to identify conserved functional complexes

  • Focus on TRIM28 binding, as position 227 is important for this interaction

• Cell-type specificity across species:

  • Immunohistochemistry to compare brain expression patterns in different species

  • Focus on cerebellar hemisphere and cerebellum where highest expression is observed in humans

  • Compare expression in neuronal versus glial cells across species

• Isoform detection and comparison:

  • Alternative splicing results in multiple transcript variants encoding the same protein

  • Western blot analysis with antibodies targeting different epitopes can detect potential species-specific isoforms

While sequence-based analyses provide the primary evidence for evolutionary selection, antibody-based approaches can validate these findings at the protein level and illuminate functional conservation across species.

What experimental design is recommended for studying PGBD1's role in transcriptional regulation and neuronal differentiation?

To investigate PGBD1's role in transcriptional regulation and neuronal differentiation, a comprehensive experimental approach should integrate the following methodologies:

• PGBD1 expression modulation:

  • Knockdown approaches using miRNA in NPCs (RNAi combined with Sleeping Beauty mediated transposition)

  • CRISPR-KRAB-MeCP2 repressor approach for promoter-specific inactivation

  • Overexpression systems with tagged PGBD1 for gain-of-function studies

• Transcriptome analysis pipeline:

  • RNA-seq on control versus PGBD1-depleted NPCs

  • Analysis of differentially expressed genes (DEGs) - previous studies identified 762 DEGs

  • GO analysis of DEGs focusing on neuronal differentiation pathways

  • qPCR validation of key differentially expressed genes

• Integration with DNA binding data:

  • Correlate transcriptome changes with ChIP-exo binding data

  • Previous studies found 212 genes (>1/3 of DEGs) with significant PGBD1 ChIP-exo signals

  • Focus on the 38 DEGs with PGBD1 binding in upstream regulatory regions

• Transcriptional pausing analysis:

  • GRO-seq to measure nascent RNA production

  • Analyze genes with multiple PGBD1 binding sites (3-7 ChIP-exo peaks) compared to those with fewer binding sites (1-2)

  • Calculate pausing indices for each gene category

• Neuronal differentiation assessment:

  • Monitor morphological changes in NPCs upon PGBD1 depletion

  • Analyze expression of neuronal marker genes (HES3, NRG1, RORA, SEMA3C, NTRK3) with known PGBD1 binding sites

  • Immunofluorescence for mature neuronal markers

This integrated approach has revealed that PGBD1 regulates genes involved in cell differentiation, nervous system development, and neurogenesis, with PGBD1 depletion promoting differentiation of neural progenitor cells .

How can I investigate potential interactions between PGBD1 and other nuclear structures using antibody-based approaches?

PGBD1's role in regulating paraspeckle formation suggests it may interact with other nuclear structures. To explore these potential interactions:

• Co-immunoprecipitation (Co-IP) strategy:

  • Use validated PGBD1 antibodies for immunoprecipitation from nuclear extracts

  • Analyze precipitated complexes by mass spectrometry

  • Confirm interactions by reciprocal Co-IP with antibodies against identified partners

  • Western blot analysis for known paraspeckle components (SFPQ, NONO, PSPC1)

• Proximity ligation assay (PLA):

  • Detect protein-protein interactions in situ

  • Combine antibodies against PGBD1 and suspected interacting partners

  • Particularly useful for detecting interactions with paraspeckle components

  • Can provide spatial resolution of interactions within nuclear compartments

• Immunofluorescence co-localization:

  • Multi-color immunofluorescence using antibodies against PGBD1 and nuclear structure markers

  • Published data show PGBD1 is predominantly nuclear and diffusely distributed in NPCs

  • Compare PGBD1 localization in NPCs versus differentiated neurons

  • Co-stain with SFPQ to examine relationship to paraspeckles

• Combined RNA-protein analysis:

  • RNA immunoprecipitation (RIP) using PGBD1 antibodies to identify associated RNAs

  • Focus on NEAT1 and other potential RNA interactions

  • RIP-seq for genome-wide identification of RNA interactions

• Super-resolution microscopy approaches:

  • STORM or PALM imaging using PGBD1 antibodies

  • Examine nano-scale organization of PGBD1 relative to nuclear structures

  • 3D reconstruction of PGBD1 distribution relative to paraspeckles

When investigating nuclear structure interactions, it's important to note that paraspeckles are not typically detectable in NPCs but appear upon differentiation . PGBD1 depletion leads to premature formation of paraspeckles in NPCs, visualized by NEAT1_2 FISH combined with SFPQ immunostaining .

What are the common issues encountered when using PGBD1 antibodies for Western blotting and how can they be resolved?

When working with PGBD1 antibodies in Western blotting applications, researchers may encounter several technical challenges:

• High molecular weight (~93 kDa) detection issues:

  • Problem: Incomplete transfer of large proteins

  • Solution: Extend transfer time or use wet transfer systems with lower percentage gels (8-10% recommended)

  • Validation: PGBD1 has been successfully detected in multiple cell lines (HeLa, Jurkat, 293, K562) showing the expected 93 kDa band

• Multiple bands or non-specific binding:

  • Problem: Detection of non-target proteins

  • Solution: Optimize antibody dilution (1:1000-1:10000 range validated) , increase blocking time, and use TBST with 5% non-fat milk

  • Alternative: Try antibodies targeting different PGBD1 epitopes (C-terminal , internal region , or N-terminal)

• Weak signal in neuronal samples:

  • Problem: Variable expression levels across differentiation stages

  • Context: PGBD1 expression is highest in NPCs and decreases upon differentiation

  • Solution: Load more protein for differentiated neurons, optimize extraction protocol for nuclear proteins, use enhanced chemiluminescence detection systems

• Inconsistent results across experiments:

  • Problem: Variable antibody performance

  • Solution: Maintain consistent antibody lots, standardize protein extraction methods, include positive controls (HEK293 or HeLa cells show robust expression)

  • Recommendation: Consider using recombinant PGBD1 protein as a positive control standard

• Detection of alternatively spliced variants:

  • Context: Alternative splicing results in multiple transcript variants encoding the same protein

  • Solution: Use antibodies targeting conserved regions present in all isoforms

  • Analysis: Document all detected bands and compare to predicted sizes of known variants

For optimal results, researchers should validate PGBD1 antibodies in their specific experimental system before proceeding with larger studies, especially when examining different neural cell types or differentiation stages.

How can I optimize immunofluorescence protocols for PGBD1 detection in neural tissues and cells?

Optimizing immunofluorescence protocols for PGBD1 detection in neural tissues requires careful consideration of fixation, permeabilization, and antibody conditions:

• Fixation optimization:

  • Validated method: 4% paraformaldehyde has been successfully used for PGBD1 detection in 293 cells

  • For neural tissues: Consider shorter fixation times (10-15 minutes) to preserve antigenicity

  • Alternative fixatives: Test methanol fixation for epitopes sensitive to cross-linking fixatives

• Permeabilization considerations:

  • PGBD1 is predominantly nuclear, requiring efficient nuclear permeabilization

  • Recommended: 0.1-0.3% Triton X-100 in PBS for 10-15 minutes

  • For tissue sections: Increase permeabilization time or concentration

• Antibody dilution and incubation:

  • Validated dilution: 1:500 for PGBD1 antibody in cell lines

  • For neural tissues: Start with 1:200-1:500 range and optimize

  • Incubation: Overnight at 4°C for primary antibodies to improve signal-to-noise ratio

• Signal amplification strategies:

  • Tyramide signal amplification for low-abundance detection

  • Biotin-streptavidin systems for enhanced sensitivity

  • Consider fluorophore brightness (Alexa Fluor dyes preferred over FITC)

• Co-staining optimization:

  • Nuclear counterstain: DAPI works well with PGBD1 nuclear staining

  • Neural markers: Combine with NeuN (neurons), GFAP (astrocytes), or progenitor markers (Nestin, Sox2)

  • Paraspeckle analysis: Co-stain with SFPQ as successfully demonstrated in previous studies

• Validation controls:

  • PGBD1 knockdown/knockout cells as negative controls

  • Cell types with known expression patterns (NPCs show higher expression than neurons)

When analyzing PGBD1 localization, note that in NPCs, PGBD1 shows predominantly nuclear and diffuse distribution, while in PGBD1-depleted cells, nuclear bodies marked by SFPQ can be observed, indicating paraspeckle formation .

How should I interpret differences in PGBD1 expression patterns across neural cell types and differentiation stages?

Interpreting PGBD1 expression patterns requires consideration of cell-type specificity and developmental regulation:

• Expression hierarchy across neural lineages:

  • Highest expression: Cerebellar hemisphere (median 18.59 TPM) and cerebellum (median 17.49 TPM)

  • Cell-type specificity: Excitatory/inhibitory neurons > oligodendrocytes > oligodendrocyte precursor cells > astrocytes

  • Interpretation: PGBD1 may have neuron-specific functions distinct from glial roles

• Developmental regulation:

  • Expression gradient: hESCs > NPCs > differentiated neurons

  • Human vs. chimpanzee: Higher expression in human cells compared to chimpanzee

  • Interpretation: PGBD1 likely regulates early neural development and progenitor maintenance

• Quantitative analysis approaches:

  • RT-qPCR: For relative quantification across samples

  • Western blot: For protein-level confirmation using validated antibodies

  • Single-cell transcriptomics: To resolve heterogeneity within populations

• Functional implications of expression patterns:

  • NPC-specific expression correlates with suppression of paraspeckle formation

  • Decreased PGBD1 in differentiation correlates with increased NEAT1_2 and paraspeckle formation

  • Knockdown experiments show PGBD1 depletion promotes differentiation

• Experimental validation strategies:

  • Compare mRNA and protein levels (not always correlated)

  • Use multiple antibodies targeting different epitopes

  • Include cell-type-specific markers in co-staining experiments

When analyzing PGBD1 expression data, researchers should consider that the protein plays a key role in maintaining the progenitor state, with its downregulation being a requirement for neuronal differentiation . This explains the observed expression gradient across differentiation stages and suggests PGBD1 as a potential regulator of neural stem cell fate decisions.

What criteria should be used to evaluate the specificity and sensitivity of PGBD1 antibodies in research applications?

Rigorous evaluation of PGBD1 antibodies requires comprehensive assessment of specificity and sensitivity across applications:

• Specificity assessment criteria:

  • Target validation: Detection of endogenous PGBD1 at expected molecular weight (92.5-93 kDa)

  • Knockout/knockdown controls: Signal reduction in PGBD1-depleted samples

  • Cross-reactivity: Absence of signal in non-target species or tissues

  • Epitope competition: Signal reduction when pre-incubated with immunizing peptide

  • Multiple antibody concordance: Similar results with antibodies targeting different epitopes

• Sensitivity evaluation:

  • Detection limits: Minimum protein concentration detectable in Western blots

  • Signal-to-noise ratio: Clean background versus specific signal

  • Dynamic range: Linear relationship between protein quantity and signal intensity

  • Reproducibility: Consistent results across experimental replicates

• Application-specific validation:

  Application	Validation Criteria	Quality Control Measure
  Western Blot	Single band at correct MW	Positive controls (HeLa, Jurkat, 293, K562 cells)
  IHC/ICC	Nuclear localization pattern	Comparison with published patterns
  ChIP	Enrichment at known targets	Motif recovery analysis
  IP	Pulldown of target protein	Mass spectrometry confirmation

• Antibody technical specifications to evaluate:

  • Clonality: Monoclonal (EPR13883) versus polyclonal options

  • Host species: Rabbit host predominant for available antibodies

  • Immunogen design: Synthetic peptides versus recombinant proteins

  • Purification method: Antigen affinity purification versus protein A column methods

• Documentation requirements:

  • Full blots/images with molecular weight markers

  • Positive and negative control data

  • Validated dilution ranges for each application

  • Lot-to-lot consistency assessment

When publishing research using PGBD1 antibodies, researchers should report detailed validation data and antibody specifications to ensure reproducibility and reliable interpretation of results.

What emerging technologies could enhance the study of PGBD1 function in neurodevelopmental disorders?

Several innovative technologies show promise for advancing PGBD1 research in the context of neurodevelopmental disorders:

• Single-cell multi-omics approaches:

  • Single-cell RNA-seq combined with ATAC-seq to correlate PGBD1 expression with chromatin accessibility

  • Single-cell proteomics to detect PGBD1 protein levels at cellular resolution

  • Spatial transcriptomics to map PGBD1 expression patterns in intact brain tissues

  • Application: Could reveal cell-type-specific PGBD1 functions in neurodevelopmental contexts

• Advanced genome editing techniques:

  • Base editing or prime editing for introducing specific mutations in PGBD1

  • Inducible or cell-type-specific CRISPR systems for temporal control of PGBD1 expression

  • CRISPR activation/repression systems to modulate PGBD1 expression without altering sequence

  • Application: Could determine how specific PGBD1 variants affect neuronal differentiation and function

• Brain organoid technologies:

  • PGBD1 knockout/knockdown in human iPSC-derived brain organoids

  • Long-term culture systems to study PGBD1's role in neurodevelopmental trajectories

  • Patient-derived organoids harboring PGBD1 variants

  • Application: Could provide human-specific insights impossible to obtain in animal models

• In vivo imaging of PGBD1 dynamics:

  • CRISPR-based tagging of endogenous PGBD1 for live imaging

  • Optogenetic control of PGBD1 expression or activity

  • Fluorescent biosensors to detect PGBD1-DNA interactions in living cells

  • Application: Could reveal the dynamics of PGBD1 regulation during neural development

• Integrative computational approaches:

  • Machine learning to identify patterns in PGBD1 binding sites and regulated genes

  • Network analysis to place PGBD1 in broader regulatory contexts

  • Prediction of structural effects of PGBD1 variants

  • Application: Could identify convergent pathways affected by PGBD1 dysfunction across disorders

Given PGBD1's role in regulating neuronal differentiation and paraspeckle formation , these technologies could illuminate how its dysfunction contributes to neurodevelopmental disorders where neural progenitor regulation is disrupted.

How can researchers integrate PGBD1 antibody-based studies with other methodologies to build a comprehensive understanding of its function?

Building a comprehensive understanding of PGBD1 function requires integration of antibody-based techniques with complementary methodologies:

• Integrative genomics approach:

  • ChIP-exo with PGBD1 antibodies to identify binding sites

  • RNA-seq after PGBD1 modulation to identify regulated genes

  • ATAC-seq to correlate binding with chromatin accessibility changes

  • Methylation analysis to explore epigenetic regulation

  • Integration framework: Correlate binding patterns with expression changes and chromatin states

• Structural biology integration:

  • Antibody epitope mapping to identify functional domains

  • Cryo-EM or X-ray crystallography of PGBD1 protein complexes

  • Hydrogen-deuterium exchange mass spectrometry to identify interaction surfaces

  • Computational modeling of DNA binding

  • Integration framework: Relate structural features to binding patterns identified by ChIP

• Functional genetics pipeline:

  • CRISPR screens targeting PGBD1-regulated genes

  • Rescue experiments with wild-type and mutant PGBD1 in knockout backgrounds

  • Domain-swapping experiments to identify key functional regions

  • Evolutionary analysis of conserved regions

  • Integration framework: Link genetic perturbations to cellular phenotypes and molecular functions

• Cell biology multi-modal analysis:

  • Live-cell imaging of PGBD1 dynamics using antibodies or tagged proteins

  • Super-resolution microscopy of nuclear organization

  • Proximity labeling (BioID/APEX) to identify interaction partners

  • Single-molecule tracking of PGBD1-DNA interactions

  • Integration framework: Correlate subcellular localization with function across cell states

• Translational research connections:

  • Patient sample analysis using validated PGBD1 antibodies

  • iPSC models from patients with neurodevelopmental disorders

  • Correlation of PGBD1 levels with clinical phenotypes

  • Testing of compounds that modulate PGBD1 activity

  • Integration framework: Connect basic mechanisms to disease relevance